{"id":452,"date":"2025-02-10T14:32:23","date_gmt":"2025-02-10T14:32:23","guid":{"rendered":"https:\/\/rttrialsqa.org.uk\/?page_id=452"},"modified":"2025-02-10T15:07:32","modified_gmt":"2025-02-10T15:07:32","slug":"tourist","status":"publish","type":"page","link":"https:\/\/rttrialsqa.org.uk\/?page_id=452","title":{"rendered":"TOURIST"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Thoracic Umbrella Radiotherapy Study in stage IV NSCLC \u2013 TOURIST<\/strong><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\n\n\n\n
\"\"<\/figure>\n\n\n\n

Prospective, randomised, multicentre trial of first line systemic treatment and radiotherapy in stage IV non-small cell lung cancer<\/strong><\/h3>\n\n\n\n
Trial Summary & Schema:<\/strong><\/h5>\n\n\n\n

PRINCE is a multicentre, phase III, parallel group, randomised controlled trial with clinical and cost effectiveness, process evaluation and translational research. 472 participants, recruited over a 42-month period, will be randomised (1:1) to control or early high-dose palliative radiotherapy; all trial patients will receive first-line systemic therapy to determine the impact of the addition of early high-dose palliative thoracic radiotherapy on quality of life (QoL) in patients with stage IV NSCLC receiving first-line standard of care systemic therapy.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
PRINCE RT QA Summary:<\/strong><\/h5>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td>1 Document filled in for both PRINCE and QUARTZ LUNG<\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>1 Case<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>1 Case<\/td>\n<\/tr>\n
Dummy Run<\/td><\/td><\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Retrospective: At least the 1st case submitted at each centre and 10% of total cases
\n
\n*Further prospective and\/or timely retrospective reviews may be deemed necessary at the discretion of the RTTQA group and the trial CI.<\/td>\n<\/tr>\n
Data collection<\/td><\/td><\/td>\n<\/tr>\n
Dosimetry <\/td>Pre-accrual Lung or Spine SABR audits<\/td>\"\"<\/td>All patients<\/td>\n<\/tr>\n
QA Streamlining<\/td>All activities<\/td>\"\"<\/td>ADSCAN (+ other lung trials)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA Contact:<\/strong> enh-tr.touristqa@nhs.net<\/a><\/p>\n\n\n\n

Chief Investigator:<\/strong> Dr. David Woolf<\/p>\n\n\n\n

PRINCE Candidate Chief Investigator:<\/strong> Professor Matthew Hatton<\/p>\n\n\n\n

Trial Coordination Centre: <\/strong>Southampton Clinical Trials Unit (SCTU) tourist@soton.ac.uk<\/a><\/p>\n\n\n\n

Sponsor: <\/strong>The Christie NHS Foundation Trust (the-christie.sponsoredresearch@nhs.net<\/a>), PRINCE (tourist-prince@soton.ac.uk<\/a>), QUARTZ LUNG (tourist-quartz@soton.ac.uk<\/a>)<\/p>\n\n\n\n

Funder:<\/strong> NIHR<\/p>\n\n\n\n

\n\n\n\n
\"\"<\/figure>\n\n\n\n

Quality of life After Radiotherapy Treatment for patients with stage IV non-small cell Lung cancer<\/strong><\/h3>\n\n\n\n
Trial summary and schema:<\/strong><\/h5>\n\n\n\n

QUARTZ LUNG is a multi-centre phase III randomised control trial (RCT) with two treatment arms (1:1 randomisation). This trial is a CST within the TOURIST platform trial. 448 participants, recruited over a 42-month period, will be randomised (1:1) to the addition of thoracic radiotherapy to symptomatic palliative care to determine the clinical effectiveness of early low-dose palliative thoracic radiotherapy on overall survival, quality of life, lung cancer symptoms, acute and late toxicity. Follow up by patient-selected mode will be used for the PROMs data collection and to measure health utility with primary and secondary outcomes as listed in the main protocol document.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
QUARTZ RT QA Summary:<\/strong><\/h5>\n\n\n\n

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.<\/em><\/p>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
QA Process<\/th>QA Activity<\/th>Required for Trial<\/th>Additional Details<\/th>\n<\/tr>\n<\/thead>\n
Pre-Accrual<\/td>Facility Questionnaire<\/td>\"\"<\/td>1 Document filled in for both PRINCE and QUARTZ LUNG<\/td>\n<\/tr>\n
Outlining Benchmark Case<\/td>\"\"<\/td>1 Case (*in cases where 2D applied field technique is not used for treatment)<\/td>\n<\/tr>\n
Planning Benchmark Case<\/td>\"\"<\/td>1 Case (*in cases where 2D applied field technique is not used for treatment)<\/td>\n<\/tr>\n
Dummy Run<\/td>\"\"<\/td>*if a centre is using a 2D applied field treatment planning technique<\/td>\n<\/tr>\n
During Accrual<\/td>Individual Case Review<\/td>\"\"<\/td>Retrospective: At least the 1st case submitted at each centre and 10% of total cases
\n
\n*Further prospective and\/or timely retrospective reviews may be deemed necessary at the discretion of the RTTQA group and the trial CI.<\/td>\n<\/tr>\n
Data collection<\/td><\/td><\/td>\n<\/tr>\n
Dosimetry <\/td>Pre-accrual Lung or Spine SABR audits<\/td>\"\"<\/td>All patients<\/td>\n<\/tr>\n
QA Streamlining<\/td>All activities<\/td>\"\"<\/td>ADSCAN (+ other lung trials)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n

RTTQA Contact: <\/strong>enh-tr.touristqa@nhs.net<\/p>\n\n\n\n

Chief Investigator: <\/strong>Dr. David Woolf<\/p>\n\n\n\n

Trial Coordination Centre:<\/strong> Southampton Clinical Trials Unit (SCTU) tourist@soton.ac.uk<\/p>\n\n\n\n

Sponsor:<\/strong> The Christie NHS Foundation Trust (the-christie.sponsoredresearch@nhs.net<\/a>), QUARTZ LUNG (tourist-quartz@soton.ac.uk<\/a>)<\/p>\n\n\n\n

Funder:<\/strong> NIHR<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Thoracic Umbrella Radiotherapy Study in stage IV NSCLC \u2013 TOURIST Prospective, randomised, multicentre trial of first line systemic treatment and radiotherapy in […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-452","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=452"}],"version-history":[{"count":7,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/452\/revisions"}],"predecessor-version":[{"id":487,"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=\/wp\/v2\/pages\/452\/revisions\/487"}],"wp:attachment":[{"href":"https:\/\/rttrialsqa.org.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}